Patients with chronic kidney disease (CKD) are often 25(OH)D 3 and 1,25(OH) 2 D 3 insufficient. We studied whether vitamin D repletion could correct aberrant adipose tissue and muscle metabolism in a mouse model of CKD-associated cachexia. Intraperitoneal administration of 25(OH)D 3 and 1,25(OH) 2 D 3 (75 μg/kg/day and 60 ng/kg/day respectively for 6 weeks) normalized serum concentrations of 25(OH)D 3 and 1,25(OH) 2 D 3 in cKD mice. Vitamin D repletion stimulated appetite, normalized weight gain, and improved fat and lean mass content in CKD mice. Vitamin D supplementation attenuated expression of key molecules involved in adipose tissue browning and ameliorated expression of thermogenic genes in adipose tissue and skeletal muscle in cKD mice. Furthermore, repletion of vitamin D improved skeletal muscle fiber size and in vivo muscle function, normalized muscle collagen content and attenuated muscle fat infiltration as well as pathogenetic molecular pathways related to muscle mass regulation in CKD mice. RNAseq analysis was performed on the gastrocnemius muscle. Ingenuity Pathway Analysis revealed that the top 12 differentially expressed genes in CKD were correlated with impaired muscle and neuron regeneration, enhanced muscle thermogenesis and fibrosis. Importantly, vitamin D repletion normalized the expression of those 12 genes in CKD mice. Vitamin D repletion may be an effective therapeutic strategy for adipose tissue browning and muscle wasting in cKD patients. Chronic kidney disease (CKD)-associated cachexia is a complex metabolic disorder that consists of anorexia, weight loss, loss of adipose tissue and muscle mass as well as hypermetabolism 1,2. Current therapies focus on palliation, but calorie supplementation alone is not successful in treating CKD-associated cachexia 3. Brown adipocytes and beige adipocytes, which reside within white adipose tissue (WAT), significantly contribute to whole body energy expenditure 4. Beige adipocytes respond to cold stimulation in a process described as WAT browning 5. We and others have demonstrated the presence of WAT browning in CKD mice 5 amongst other animal disease models of cachexia as well as in patients with cachexia 6-9. We also demonstrated WAT browning in a mouse model of cystinosis, a genetic cause of CKD 10,11. CKD patients have a high prevalence of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 insufficiency 12-14. Vitamin D insufficiency 2,12 may be an important cause of CKD-associated cachexia. Vitamin D influences myogenesis and muscle function 15,16. Furthermore, vitamin D insufficiency has been correlated